Pharmacogenetics and treatment-resistant schizophrenia

Adriana Foster; Peter F. Buckley

doi:10.1007/978-3-642-45257-4_12

Pharmacogenetics and treatment-resistant schizophrenia

Adriana Foster, Peter F. Buckley

Psychiatry and Health Behavior

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.

Original language	English (US)
Title of host publication	Treatment-Refractory Schizophrenia: A Clinical Conundrum
Publisher	Springer Berlin Heidelberg
Pages	179-194
Number of pages	16
ISBN (Print)	9783642452574, 9783642452567
DOIs	https://doi.org/10.1007/978-3-642-45257-4_12
State	Published - Jan 1 2014

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-3-642-45257-4_12

Cite this

@inbook{1f57e050a30d47a89f1d3a02040520dd,

title = "Pharmacogenetics and treatment-resistant schizophrenia",

abstract = "It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.",

author = "Adriana Foster and Buckley, {Peter F.}",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/978-3-642-45257-4_12",

language = "English (US)",

isbn = "9783642452574",

pages = "179--194",

booktitle = "Treatment-Refractory Schizophrenia: A Clinical Conundrum",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Pharmacogenetics and treatment-resistant schizophrenia

AU - Foster, Adriana

AU - Buckley, Peter F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.

AB - It should not be lost on our field that the therapeutics of oncology has been transformed by the incorporation of genetic information into drug selection as well as the evaluation of efficacy and adverse effects for each individual treatment. There is accumulating evidence that genetic polymorphisms of several neurotransmitters related to schizophrenia can be useful in predicting both treatment response and propensity to experience side effects during the treatment of patients with schizophrenia. Believing that more severe, refractory schizophrenia might constitute a patient subgroup of some distinct neurobiological signature(s), the evolution of pharmacogenetic studies into clinical practice would be a real advance to clinicians who inevitably today struggle with “trial-and-error” pharmacologic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84956772746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956772746&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-45257-4_12

DO - 10.1007/978-3-642-45257-4_12

M3 - Chapter

AN - SCOPUS:84956772746

SN - 9783642452574

SN - 9783642452567

SP - 179

EP - 194

BT - Treatment-Refractory Schizophrenia: A Clinical Conundrum

PB - Springer Berlin Heidelberg

ER -

Pharmacogenetics and treatment-resistant schizophrenia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this